{
    "clinical_study": {
        "@rank": "125875", 
        "arm_group": [
            {
                "arm_group_label": "G+M", 
                "arm_group_type": "Experimental", 
                "description": "Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg"
            }, 
            {
                "arm_group_label": "C", 
                "arm_group_type": "Experimental", 
                "description": "Combination of gemigliptin50mg/metformin HCl extended release 1000mg"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics of\n      the combinations of gemigliptin 50mg and metformin HCl extended release 1000mg in comparison\n      to each component administered in healthy male volunteers."
        }, 
        "brief_title": "BE Study of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered Alone", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age between 20 to 45, healthy male subjects(at screening)\n\n          -  Body weight between 55kg - 90kg, BMI between 18.0 - 27.0\n\n          -  FPG 70-125mg/dL glucose level(at screening)\n\n          -  Subject who totally understand the progress of this clinical trials, make decision by\n             his free will, and signed a consent form to follow the progress.\n\n        Exclusion Criteria:\n\n          -  Subject who has past or present history of any diseases following below.(liver\n             including hepatitis virus carrier, kidney,\n             Neurology,immunology,pulmonary,endocrine,hematooncology,cardiology,mental disorder.)\n\n          -  Subject who had GI tract disease or(ulcer, acute or chronic pancreatitis)\n             surgery.(appendectomy, hernioplasty are not included)\n\n          -  Subject who had drug hypersensitivity reaction.(Aspirin, antibiotics)\n\n          -  Subject who already participated in other trials in 3months\n\n          -  Subject who had whole blood donation in 2months, or component blood donation in\n             1months or transfusion in 1months currently.\n\n          -  Smokers.(but, if the subject did'nt smoke in 3months, can participate the trial)"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "27", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662674", 
            "org_study_id": "LG-DMCL002"
        }, 
        "intervention": [
            {
                "arm_group_label": "G+M", 
                "description": "Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day", 
                "intervention_name": "gemigliptin and metformin HCl extended release", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "C", 
                "description": "Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.", 
                "intervention_name": "gemigliptin/metformin HCl extended release", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul National University Hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Open-label, Oral Single Dosing, Two-way Crossover Clinical Trial to Compare the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of the Combinations of Gemigliptin 50mg and Metformin HCl Extended Release 1000mg in Comparison to Each Component Administered in Healthy Male Volunteers", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "South Korea: Korea Food and Drug Administration (KFDA)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "To evaluate AUClast of gemigliptin and metformin", 
                "measure": "AUClast", 
                "safety_issue": "No", 
                "time_frame": "up to 48h post-dose"
            }, 
            {
                "description": "To evaluate Cmax of gemigliptin and metformin", 
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "up to 48h post-dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662674"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "This parameter is been used to measure pharmarcodynamic characters of gemigliptin and metformin, the supression rate of DPP4 activity.", 
            "measure": "AUEC", 
            "safety_issue": "No", 
            "time_frame": "up to 48h post-dose"
        }, 
        "source": "LG Life Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LG Life Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}